What do you do, with an M protein?

Size: px
Start display at page:

Download "What do you do, with an M protein?"

Transcription

1 What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca

2 Disclosure of Potential for Conflict of Interest Name of presenter: Emily Rimmer Name of presentation: What do you do, with an M protein? FINANCIAL DISCLOSURE Grants/Research Support: None Speaker bureau/honoraria amounts: None Consulting fees: None Other: None

3 Objectives List the most common indications for ordering a serum protein electrophoresis (SPEP) Understand the difference between a polyclonal and monoclonal gammopathy Develop a logical approach to the investigation of an M-protein

4 Monoclonal Gammopathies n = 46,739 Lymphoproliferative SMM 4% (1,780) N = 46,739 3% (1,410) Solitary or extramedullary AL amyloidosis plasmacytoma 2% (899) 9.5% (4,490) Macro 2.5% (1,236) Multiple Myeloma 18% (8,336) Other 4% (2,036) MGUS 57% (26,552) Mayo Clinic

5 Definition of monoclonal protein Monoclonal immunoglobulin secreted by an abnormally expanded clone of plasma cells in an amount that can be detected by immunofixation of serum and/or urine/other fluids Also know as: M protein Paraprotein M-spike M-component M-band

6

7 Type of M-protein Intact immunoglobulin (heavy & light chain) Light chain only Heavy chain only Associated plasma cell disorders Myeloma Other lymphoproliferative disorders Waldrenstrom macroglobulinemia Light chain myeloma Light chain deposition disease (usually kappa) AL amyloidosis (usually lambda) Heavy chain disease (alpha, gamma, mu) Heavy chain deposition disease

8 When to order an SPEP to look for an M band? To make a diagnosis: When clinically suspicious of the disorders associated with an M band Unexplained anemia / weakness / fatigue / ESR Unexplained renal insufficiency Heavy proteinuria in patient >40yrs Bence Jones proteinuria Hypercalcemia Hypergammaglobulinemia Immunoglobulin deficiency Peripheral neuropathy (5% will have MGUS) Recurrent infections Unexplained bone pain / pathologic fracture / lytic lesion

9 When to order an SPEP to look for an M band? For prognosis: Risk of progression into symptomatic disease for MGUS and smoldering myeloma For monitoring: Response assessment Progression/relapse

10 Serum Protein ElectroPhoresis Serum protein migrate into bands based on their size and charge Limitations: Not sensitive when M- protein is small Cannot classify type of M-protein

11 Serum immunofixation Used to determine clonality Monoclonal versus polyclonal Not able to quantitate the concentration of the M band Must be done in conjunction with the SPEP Does not give the concentration of the M- protein

12 SPEP interpretation Normal No M protein present

13 SPEP interpretation Polyclonal gammopathy Liver disease Connective tissue disease Chronic infection normal Polyclonal pattern

14 SPEP - Interpretation Monoclonal gammopathy

15 Biclonal gammopathy IgG lambda IgM kappa

16 Beyond the SPEP If only SPEP is done about 15% of myeloma/other disorders WILL BE MISSED because SPEP will be negative

17 Bence Jones protein: are you still testing urine? (UPEP) Batched test with slow turnaround. Incomplete 24 hr collection. Urine smelly Labour intensive Based on renal metabolism Less sensitive and non numerical. What is the alternative? Testing the serum for free light chains Serum free light chain analysis: Bradwell AR 2008

18 Serum Free light chain index (SFLCI) Does not rely on urine collection nor renal function Diagnosis Non-secretory, oligosecretory, light chain myeloma, and amyloidosis Prediction of risk of progression for MGUS, smoldering myeloma, and plasmacytoma More sensitive than SPEP for monitoring for residual disease

19 AND

20 Diagnostic criteria MGUS SMM MM M protein in serum <30g/l and M protein >30g/l and / or Any level of M protein (none in non-secretory) and Clonal BMPCS<10% and low level of infiltration on trephine and Clonal BMPCS >10% and Clonal BMPCS >10% and No myeloma related CRAB No evidence of other B cell LPD or light chain associated Amyloidosis or other tissue damage No myeloma related CRAB Myeloma related CRAB Kyle et al, Leukemia 2010;24:1121-7

21 Myeloma related CRAB C = hypercalcemia (Ca >2.8mmol/L) R = renal failure (Cr >173) A = anemia (Hb<100 or > 20g below baseline) B = bony lesions (lytics, severe osteopenia, pathological fractures or plasmacytoma) Others: nephrotic syndrome, constitutional symptoms, neuropathy, hepatosplenomegaly etc

22 MGUS is common Kyle et al, NEJM 2006;354:1362-9

23 Risk of progression of MGUS to Myeloma 58% = HIGH RISK 37% 21% 5% = LOW RISK 3 adverse risk factors: 1. M band >15g/L 2. Non-IgG subtype 3. Abnormal FLC ratio (<0.25 or >4) Rajkumar et al, Blood 2005;106:812-7

24 Risk of progression of SMM to Myeloma 10%/year 3%/year 1%/year 3 risk factors: 1. M band >30g/L 2. Bone marrow Plasmacytosis >10% 3. Abnormal FLC ratio (<0.125 or >8)

25 Biology of response and relapse in MM: a treatable but at this time, incurable malignancy 10 Asymptomatic Symptomatic M protein (g/dl) 5 2 MGUS or smouldering myeloma Active myeloma Plateau remission Relapse Refractory relapse Therapy Therapy Therapy ~ 31,500 cases annually in Europe ~21,500 deaths annually in Europe International Agency for Research on Cancer (IARC) GLOBOCAN Available from: www-dep.iarc.fr/

26 Goals of therapy Overall response rate (ORR) CR: strict or unconfirmed VGPR PR Quality of response Event free or progression free survival Overall survival strongly associated with the quality of response

27 Current standard of care in Manitoba Transplant eligible Induction chemotherapy: x 3-4 cycles Bortezomib/Dexamethasone 40mg D1-4, 9-12, Adding cyclophosphamide for suboptimal response Upfront HDT-ASCT Followed by maintenance therapy: thalidomide, lenalidomide Transplant ineligible Few comorbidities: bortezomib-based regimens or Imid based VMP, V-CWAP Rd, MPT, MPR Multiple comorbidities/poor performance status MP (melphalan & prednisone) CWAP (cyclophosphamide with alternating prednisone)

28 Take Home Message Monoclonal proteins are common Order an SPEP / immunofixation when clinically suspicious of the disorders associated with an M band When an M band is identified investigate for myeloma related CRAB symptoms referral to hematologist is appropriate

29 Questions

Elevated Immunoglobulins and Paraproteins

Elevated Immunoglobulins and Paraproteins Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

June Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD

June Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD June 2011 Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD In this issue we review the laboratory work up of patients suspected of having a plasma cell neoplasm. As the range in clinical

More information

Applicazioni della misura delle Free Light Chain nella pratica clinica. Maria Teresa Petrucci

Applicazioni della misura delle Free Light Chain nella pratica clinica. Maria Teresa Petrucci Applicazioni della misura delle Free Light Chain nella pratica clinica Maria Teresa Petrucci Serum free light chain immunoassay Heavy chain Kappa Light chain Hidden surface Lambda Exposed surface Serum

More information

Guidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology

Guidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Guidelines for the diagnosis of Multiple Myeloma 2014 By:British Committee for Standards in Haematology (BCSH) Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Diagnosis, prognostic factors and disease monitoring

More information

Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory

Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional

More information

Southern Derbyshire Shared Care Pathology Guidelines. Diagnosis and Management of Myeloma

Southern Derbyshire Shared Care Pathology Guidelines. Diagnosis and Management of Myeloma Southern Derbyshire Shared Care Pathology Guidelines Diagnosis and Management of Myeloma When to screen for Myeloma and related disorders Not recommended to screen the normal population Clinical Symptoms,

More information

Parameswaran Hari Medical College of Wisconsin Milwaukee

Parameswaran Hari Medical College of Wisconsin Milwaukee Multiple Myeloma Linking the clinical course to report forms Parameswaran Hari Medical College of Wisconsin Milwaukee 45,000 Annual Numbers of Blood and Marrow Transplants Worldwide 1970-2003 40,000 Number

More information

بسم اهلل الرمحن الرحيم

بسم اهلل الرمحن الرحيم بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;

More information

Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory

Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional

More information

Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know

Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pr e- B-ce ll B-ce ll Transformed B-ce ll Plasma cell Ig Su rf ace Su rf ace Secre ted Major malignant

More information

acute leukemia precursor chronic leukemia lymphoma

acute leukemia precursor chronic leukemia lymphoma Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated t d Pre- B-cell B-cell Ig Surface Transformed B-cell Surface Plasma cell Secreted Major malignant counterpart

More information

Diagnosis and Current Standard Treatments for Multiple Myeloma. Natalie S. Callander, M.D Professor of Medicine

Diagnosis and Current Standard Treatments for Multiple Myeloma. Natalie S. Callander, M.D Professor of Medicine Diagnosis and Current Standard Treatments for Multiple Myeloma Natalie S. Callander, M.D Professor of Medicine Goals Introduce and/or compliment understanding of plasma cell disorders-mgus, SMM and symptomatic

More information

Myeloma Primary Care. Dr R Lovell Feb 2015

Myeloma Primary Care. Dr R Lovell Feb 2015 Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems

More information

Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA

Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT

More information

Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population

Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 157 Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs

More information

Multiple myeloma (MM) & related disorders

Multiple myeloma (MM) & related disorders Multiple myeloma (MM) & related disorders Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial

More information

Treatment options in Myeloma. BritModis myeloma for the elderly care specialist

Treatment options in Myeloma. BritModis myeloma for the elderly care specialist Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood

More information

Multiple Myeloma Patient Handbook

Multiple Myeloma Patient Handbook Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016 MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to

More information

Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities

Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities Immunopathology / Persistence of IFE MGUS Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities David L. Murray, MD, PhD, 1 Justin L. Seningen, MD, 1 Angela Dispenzieri, MD,

More information

DIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP

DIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Majalah Patologi Klinik Indonesia dan Laboratorium Medik Page 196 2018 March; 24(2): 196-200 p-issn 0854-4263 e-issn 2477-4685 Available

More information

Laboratories and the New IMWG Myeloma Guidelines

Laboratories and the New IMWG Myeloma Guidelines Laboratories and the New IMWG Myeloma Guidelines David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu Speaker Disclosure In

More information

Multiple Myeloma Patient Handbook.

Multiple Myeloma Patient Handbook. Multiple Myeloma Patient Handbook www.myeloma.ca Introduction This resource has been designed for: 1. Someone who has been newly diagnosed with myeloma and is wondering what it means and what the future

More information

Freelite & Hevylite. Together Freelite & Hevylite catch more monoclonal gammopathy patients. The Specialist Protein Company

Freelite & Hevylite. Together Freelite & Hevylite catch more monoclonal gammopathy patients. The Specialist Protein Company Freelite & Hevylite Together Freelite & Hevylite catch more monoclonal gammopathy patients The Specialist Protein Company Freelite The Freelite assay is composed of two sensitive and specific polyclonal

More information

Freelite & Hevylite. Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies

Freelite & Hevylite. Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies Freelite & Hevylite Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies Monoclonal Gammopathy Monoclonal gammopathies are diseases of the bone marrow and are associated with

More information

Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies

Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal

More information

Diagnosis and staging

Diagnosis and staging Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing

More information

Change Summary - Form 2116 (R3) 1 of 6

Change Summary - Form 2116 (R3) 1 of 6 Change Summary - Form 2116 (R3) 1 of 6 Form Question Number (r3) Question Text Change Type Description New Text Previous Text Previous Question Number (r2) 2116 Today's date: Removed "Today's date:" was

More information

Guidelines for the diagnosis and management of Myeloma within AngCN

Guidelines for the diagnosis and management of Myeloma within AngCN Guidelines for the diagnosis and management of Myeloma within AngCN Ref: AngCN-SSG-Ha5 Cancer Standards Measure: N/A Page 1 of 11 Approved and Published: March 2013 1 Introduction These brief guidelines

More information

Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma

Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain

More information

Multiple. Powerful thinking advances the cure.

Multiple. Powerful thinking advances the cure. Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure www.arztol.com Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation

More information

Restrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials

Restrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources

More information

Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,

More information

Understanding MGUS and Smoldering Multiple Myeloma

Understanding MGUS and Smoldering Multiple Myeloma Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE

More information

diag.of gammop Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

diag.of gammop Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS laboratory diag.of gammop Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Sarrafnejad@tums.ac.ir Arne Wilhelm Kaurin Tiselius Nobel Prize for Chemistry (1948) Electrophoresis ٤ After

More information

Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014

Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014 Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins

More information

The New England Journal of Medicine A LONG-TERM STUDY OF PROGNOSIS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE. Patients

The New England Journal of Medicine A LONG-TERM STUDY OF PROGNOSIS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE. Patients A LONG-TERM STUDY OF PROGNOSIS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE ROBERT A. KYLE, M.D., TERRY M. THERNEAU, PH.D., S. VINCENT RAJKUMAR, M.D., JANICE R. OFFORD, B.S., DIRK R. LARSON, M.S.,

More information

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 Myeloma: diagnosis and management NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma

Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Clinical Chemistry 56:1 16 20 (2010) Clinical Case Study Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Kazunori Murata, 1 Raynell J. Clark, 1 Karen S. Lockington,

More information

MULTIPLE MYELOMA Disease Overview

MULTIPLE MYELOMA Disease Overview Speak to a patient support nurse PH: 1.866.603.6628 Email: patientnavigator@themmrf.org MULTIPLE MYELOMA Disease Overview Place stamp here Multiple Myeloma Research Foundation 383 Main Avenue, 5th Floor

More information

MULTIPLE MYELOMA Disease Overview

MULTIPLE MYELOMA Disease Overview MULTIPLE MYELOMA Disease Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney,

More information

This talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse

This talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is

More information

Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective

Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective *Rahman MM, 1 Aziz MA, 2 Islam MM, 3 Zaman AM, 4 Afrose S, 5 Khan MA 6 Treatment of multiple myeloma, a plasma

More information

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline: Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.

More information

Treatment strategies for relapsing and refractory myeloma

Treatment strategies for relapsing and refractory myeloma Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory

More information

Immunoglobulin / free light chain ratio

Immunoglobulin / free light chain ratio Immunoglobulin / free light chain ratio 1 1 2 Kiyotaka FUJITA Katsunori TAKAHASHI Ikunosuke SAKURABAYASHI FLC IgG, IgA, IgM, IgD, IgE 5 1 1 H 1 L H,,,, L 2 monoclonal immunoglobulinemia : M L L H 40 H

More information

Smoldering Multiple Myeloma

Smoldering Multiple Myeloma Smoldering Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive

More information

WG-ICQA Harmonisation of Interpretive Commenting EQA

WG-ICQA Harmonisation of Interpretive Commenting EQA WG-ICQA Harmonisation of Interpretive Commenting EQA WG-ICQA Subgroup: Harmonisation of reporting of protein electrophoresis and serum FLC, and quantification of small monoclonal proteins Improved patient

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 73 Effective Health Care Program Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias Executive Summary Background

More information

Hot Topic. Disclosures. None

Hot Topic. Disclosures. None Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo

More information

serum FLC concentration was available twice as often as a measurable urine M-spike American Association for Clinical Chemistry

serum FLC concentration was available twice as often as a measurable urine M-spike American Association for Clinical Chemistry Clinical Chemistry 57:12 1687 1692 (2011) Clinical Immunology Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification:

More information

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma-Cell Dyscrasias

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma-Cell Dyscrasias DRAFT Comparative Effectiveness Review Number xx Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma-Cell Dyscrasias Prepared for: Agency for Healthcare Research and

More information

CASE REPORT AND REVIEW OF THE LITERATURE

CASE REPORT AND REVIEW OF THE LITERATURE Page 76 / SA ORTHOPAEDIC JOURNAL Summer 2009 C ASE R EPORT AND R EVIEW OF THE L ITERATURE Low-secretory multiple myeloma HF Visser MBChB(Pret) Senior Registrar, Department Orthopaedic Surgery, University

More information

Handout for lecture on plasma cell neoplasms presented by Rob McKenna

Handout for lecture on plasma cell neoplasms presented by Rob McKenna Handout for lecture on plasma cell neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes

More information

Hevylite: New strategies for Diagnosis, Monitoring and Prognosis of monoclonal gammopathies

Hevylite: New strategies for Diagnosis, Monitoring and Prognosis of monoclonal gammopathies Hevylite: New strategies for Diagnosis, Monitoring and Prognosis of monoclonal gammopathies AR Bradwell. University of Birmingham and Binding Site Ltd How good are tests for monoclonal monoclonal proteins?

More information

Case Report Serum Free Light Chain Only Myeloma with Cytoplasmic IgM

Case Report Serum Free Light Chain Only Myeloma with Cytoplasmic IgM Hindawi Publishing Corporation Case Reports in Hematology Volume 2014, Article ID 676913, 5 pages http://dx.doi.org/10.1155/2014/676913 Case Report Serum Free Light Chain Only Myeloma with Cytoplasmic

More information

SIGNIFICANCE OF GAMMA GLOBULINS IN MULTIPLE MYELOMA THROUGH SERUM ELECTROPHORETIC PATTERN

SIGNIFICANCE OF GAMMA GLOBULINS IN MULTIPLE MYELOMA THROUGH SERUM ELECTROPHORETIC PATTERN WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Kumar et al. SJIF Impact Factor 6.647 Volume 6, Issue 7, 1211-1218 Research Article ISSN 2278 4357 SIGNIFICANCE OF GAMMA GLOBULINS IN MULTIPLE MYELOMA

More information

To learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation

To learn more about the MMRF, visit  or call Accredited by: 2015 Multiple Myeloma Reseach Foundation ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998

More information

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse. Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

More information

This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.

This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or

More information

FARYDAK (panobinostat) oral capsule

FARYDAK (panobinostat) oral capsule FARYDAK (panobinostat) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune

Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Original article Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Dr. Sagale MS, Dr. Dangmali DP, Dr. Rane SR, Dr. Kulkarni KK, Dr. Puranik SC Department of Pathology,

More information

Myeloma treatment algorithm 1999

Myeloma treatment algorithm 1999 Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant

More information

EDUCATIONAL COMMENTARY LABORATORY EVALUATION OF IMMUNOPROLIFERATIVE DISORDERS

EDUCATIONAL COMMENTARY LABORATORY EVALUATION OF IMMUNOPROLIFERATIVE DISORDERS Commentary provided by: Louann W. Lawrence, Dr.PH, MLS (ASCP) Professor Emeritus, Retired Louisiana State University Health Sciences Center New Orleans, LA EDUCATIONAL COMMENTARY LABORATORY EVALUATION

More information

Hematology: Understanding the Immunoglobulins and Bone Marrow Diseases. Dr. Andrea Lee Mississauga Halton Primary Care Clinic Day November 19, 2016

Hematology: Understanding the Immunoglobulins and Bone Marrow Diseases. Dr. Andrea Lee Mississauga Halton Primary Care Clinic Day November 19, 2016 Hematology: Understanding the Immunoglobulins and Bone Marrow Diseases Dr. Andrea Lee Mississauga Halton Primary Care Clinic Day November 19, 2016 Disclosures Presenter: Dr. Andrea Lee Relationships with

More information

Plasma cell neoplasms

Plasma cell neoplasms Plasma cell neoplasms WHO CLASSIFICATION OF PLASMA CELL NEOPLASMS Plasma Cell Myeloma Variants - Non-secretory myeloma Indolent myeloma Smoldering myeloma Plasma cell leukemia Plasmacytoma Solitary plasmacytoma

More information

Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins

Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins Immunopathology / DETECTING SUBTLE FLC-PRODUCING M PROTEINS Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins Nasir A, Bakshi,

More information

Your Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Your Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)

More information

A rare case of non-secretory multiple myeloma: a case report and literature review

A rare case of non-secretory multiple myeloma: a case report and literature review This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction

More information

Myeloma Expert Information About Diagnosis and Treatment

Myeloma Expert Information About Diagnosis and Treatment Slide 1: Myeloma Expert Information About Diagnosis and Treatment OPERATOR: Hello, everyone, and welcome to Myeloma Expert Information About Diagnosis and Treatment. It is my pleasure to introduce your

More information

Report of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup:

Report of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup: Report of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup: Results of an international survey of the reporting of protein electrophoresis and serum free light

More information

+ Serum Protein Electrophoresis with Immunofixation

+ Serum Protein Electrophoresis with Immunofixation + Serum Protein Electrophoresis with Immunofixation Dr.Ajay Phadke Centre Head SRL Diagnostics-Dr.Avinash Phadke s Lab + What is electrophoresis? Electrophoresis is a method of separating proteins based

More information

ABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies. An Hendrickx MSc. Scientific Advisor

ABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies. An Hendrickx MSc. Scientific Advisor ABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies An Hendrickx MSc. Scientific Advisor In this talk introduction biology of free light chains laboratorium investigation

More information

Your Test Results. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation

Your Test Results. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results U-YTR_EN_2018_j1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455

More information

Stem Cells and Multiple Myeloma

Stem Cells and Multiple Myeloma Stem Cells and Multiple Myeloma What is Multiple Myeloma Multiple Myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow Plasma cells normally make proteins called

More information

Myeloma. Anne Grace, myeloma survivor. Support for this publication provided by

Myeloma. Anne Grace, myeloma survivor. Support for this publication provided by Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2017 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about

More information

The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management

The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management I am Dr. Brian Durie at Cedars Sinai Medical Center, Los Angeles. I am also chairman of the International Myeloma Foundation, and I am very pleased today to be participating in this program with my friend

More information

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT)

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA

More information

January Northside Multiple Myeloma Support Group Meeting January 5, 2019

January Northside Multiple Myeloma Support Group Meeting January 5, 2019 January 2019 Northside Multiple Myeloma Support Group Meeting January 5, 2019 Dr. Lonial welcomed 70 people to the conference center. He reported that the Winship team is growing and they were at ASH reporting

More information

Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation

Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Original Article Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Sara L. Hall, 1 Jill Tate, 2 Devinder Gill, 1,3 *Peter Mollee 1,3

More information

Myeloma. Your Essential Guide

Myeloma. Your Essential Guide Myeloma Your Essential Guide Contents 3 Introduction 4 What is myeloma 7 Types of myeloma 9 What causes myeloma? 10 Diagnosis, tests, investigations and staging 14 Treatment of myeloma 19 Initial treatment

More information

Myeloma An Introduction. Myeloma Infoguide Series. Essentials

Myeloma An Introduction. Myeloma Infoguide Series. Essentials Myeloma An Introduction Myeloma Infoguide Series Essentials This publication has been made possible thanks to the generosity of Myeloma UK supporters. To find out how you can support our vital work call

More information

Suppression of Polyclonal Immunoglobulin Production by M-proteins Shows Isotype Specificity

Suppression of Polyclonal Immunoglobulin Production by M-proteins Shows Isotype Specificity 274 Annals of Clinical & Laboratory Science, vol. 31, no. 3, 2001 Suppression of Polyclonal Immunoglobulin Production by M-proteins Shows Isotype Specificity Liang Wang and David C. Young Department of

More information

Q1 What is your occupation/role? (select all that apply) Answered: 310 Skipped: 4 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Q1 What is your occupation/role? (select all that apply) Answered: 310 Skipped: 4 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Q1 What is your occupation/role? (select all that apply) Answered: 310 Skipped: 4 ANSWER CHOICES Pathologist Total Respondents: 310 Pathologist Physician (non-radiolo... Medical Director Technologist/Te

More information

Outcome and survival of myeloma patients diagnosed Real-world data on 4904 patients from the Swedish Myeloma Registry

Outcome and survival of myeloma patients diagnosed Real-world data on 4904 patients from the Swedish Myeloma Registry ARTICLE Plasma Cell Disorders Ferrata Storti Foundation Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry Haematologica 2018

More information

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,

More information

Screening Panels for Detection of Monoclonal Gammopathies

Screening Panels for Detection of Monoclonal Gammopathies Clinical Chemistry 55:8 1517 1522 (2009) Clinical Immunology Screening Panels for Detection of Monoclonal Gammopathies Jerry A. Katzmann, 1,2* Robert A. Kyle, 1,2 Joanne Benson, 3 Dirk R. Larson, 3 Melissa

More information

Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples

Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,

More information

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh

More information

Princess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017

Princess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017 Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been

More information

Serum Free Light Chain Assays

Serum Free Light Chain Assays Freelite Serum Free Light Chain Assays An aid to the diagnosis of: Light Chain (Bence Jones) Multiple Myeloma (LCMM) Nonsecretory Multiple Myeloma (NSMM) AL amyloidosis Light Chain Deposition Disease (LCDD)

More information

Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents

Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University

More information

Intact immunoglobulin heavy/light chain paired assays

Intact immunoglobulin heavy/light chain paired assays Intact immunoglobulin heavy/light chain paired assays Stephen Harding 1, Philip Young 1, Marina Di Fazio 2, Richard Hughes 1 1Research and Development, The Binding Site Group, Birmingham, UK 2Scientific

More information

Understanding Your Blood and Blood Tests

Understanding Your Blood and Blood Tests Myeloma Canada InfoGuide Series Understanding Your Blood and Blood Tests www.myeloma.ca Introduction This InfoGuide is for people living with myeloma, their families and their caregivers. It will help

More information

Medical Policy Manual. Topic: Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification. Date of Origin: January 2014

Medical Policy Manual. Topic: Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification. Date of Origin: January 2014 Medical Policy Manual Topic: Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Date of Origin: January 2014 Section: Genetic Testing Last Reviewed Date: January

More information